8月6日,诺和诺德发布2025年上半年财报,公司整体实现营收1549.44亿丹麦克朗(约合228.54亿美元),同比增长18%;明星药物司美格鲁肽合计收入1127.56亿丹麦克朗(约合166.83亿美元),成为今年上半年全球销售额最高的药物。从首次获批到以166亿美元的半年销售额登顶“全球药王”,司美格鲁肽用8年时间便改写了全球医药市场的格局。目前,三款相关药物已经在全球超过70个国家和地区上市。...
Source Link8月6日,诺和诺德发布2025年上半年财报,公司整体实现营收1549.44亿丹麦克朗(约合228.54亿美元),同比增长18%;明星药物司美格鲁肽合计收入1127.56亿丹麦克朗(约合166.83亿美元),成为今年上半年全球销售额最高的药物。从首次获批到以166亿美元的半年销售额登顶“全球药王”,司美格鲁肽用8年时间便改写了全球医药市场的格局。目前,三款相关药物已经在全球超过70个国家和地区上市。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.